Clinical Data Regenxbio’s Duchenne gene therapy clears phase 3 hurdle PharmaphorumRegenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche's Elevidys.Gene Therapy PlatformRead full story pharminent May 14, 2026 (Last updated: May 14, 2026) Pharmaphorum Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche’s Elevidys. Gene Therapy Platform Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA hands BeOne, Taiho approvals for blood cancersNext: Degron adds $40M to series A, supporting immunology plans for molecular glue platform Related Stories Clinical Data Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs pharminent July 14, 2026 Clinical Data Major trial launched to explore GLP-1 benefit in dementia pharminent July 13, 2026 Clinical Data GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China pharminent July 10, 2026
